Premier Path Wealth Partners LLC Has $1.24 Million Stake in Becton, Dickinson and Company (NYSE:BDX)

Premier Path Wealth Partners LLC increased its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 4.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,473 shares of the medical instruments supplier’s stock after purchasing an additional 251 shares during the period. Premier Path Wealth Partners LLC’s holdings in Becton, Dickinson and Company were worth $1,242,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of BDX. State Street Corp boosted its holdings in shares of Becton, Dickinson and Company by 0.8% in the third quarter. State Street Corp now owns 13,953,116 shares of the medical instruments supplier’s stock valued at $3,364,096,000 after buying an additional 106,616 shares during the period. Geode Capital Management LLC boosted its stake in Becton, Dickinson and Company by 1.8% in the 3rd quarter. Geode Capital Management LLC now owns 6,285,513 shares of the medical instruments supplier’s stock worth $1,510,050,000 after purchasing an additional 111,101 shares during the period. Massachusetts Financial Services Co. MA increased its holdings in Becton, Dickinson and Company by 9.4% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 5,365,554 shares of the medical instruments supplier’s stock worth $1,293,635,000 after purchasing an additional 460,440 shares in the last quarter. Ameriprise Financial Inc. raised its stake in shares of Becton, Dickinson and Company by 6.4% in the 2nd quarter. Ameriprise Financial Inc. now owns 5,055,354 shares of the medical instruments supplier’s stock valued at $1,181,483,000 after purchasing an additional 302,893 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Becton, Dickinson and Company by 79.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 2,986,543 shares of the medical instruments supplier’s stock worth $720,089,000 after buying an additional 1,317,723 shares during the period. 86.97% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, EVP Roland Goette sold 638 shares of the firm’s stock in a transaction on Monday, December 9th. The stock was sold at an average price of $219.03, for a total value of $139,741.14. Following the transaction, the executive vice president now owns 14,217 shares in the company, valued at approximately $3,113,949.51. This trade represents a 4.29 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Shana Carol Neal sold 788 shares of Becton, Dickinson and Company stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $235.00, for a total transaction of $185,180.00. Following the completion of the transaction, the executive vice president now directly owns 16,201 shares in the company, valued at $3,807,235. This trade represents a 4.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 8,747 shares of company stock worth $1,949,520 in the last quarter. 0.36% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several research firms have commented on BDX. Citigroup upgraded Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and boosted their target price for the company from $255.00 to $275.00 in a research note on Tuesday, October 1st. StockNews.com downgraded shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. Finally, Evercore ISI increased their price objective on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. One research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $283.50.

Becton, Dickinson and Company Trading Up 0.5 %

Shares of NYSE:BDX opened at $237.57 on Friday. Becton, Dickinson and Company has a 12-month low of $218.75 and a 12-month high of $248.42. The business has a 50 day moving average of $226.95 and a 200-day moving average of $232.53. The company has a quick ratio of 0.74, a current ratio of 1.17 and a debt-to-equity ratio of 0.69. The stock has a market cap of $68.90 billion, a PE ratio of 40.00, a P/E/G ratio of 1.69 and a beta of 0.39.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $3.81 EPS for the quarter, beating analysts’ consensus estimates of $3.77 by $0.04. The firm had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. The company’s revenue for the quarter was up 6.9% on a year-over-year basis. During the same period in the prior year, the firm posted $3.42 EPS. As a group, equities research analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, December 31st. Investors of record on Monday, December 9th were given a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a yield of 1.75%. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. The ex-dividend date of this dividend was Monday, December 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 70.03%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.